Key Financials Snapshot

TTM · Consolidated · ₹ in Cr
Market Cap
₹4870 Cr.
Stock P/E
28
P/B
5.1
Current Price
₹1616.3
Book Value
₹ 318.8
Face Value
10
52W High
₹1836
52W Low
₹ 1394
Dividend Yield
1.36%

Care Ratings Overview

Business

Care Ratings Ltd. is a leading credit rating agency in India. Its core business involves assessing and assigning credit ratings to various debt instruments, bank loans, and other financial obligations of corporates, financial institutions, and public sector undertakings. It also provides ratings for initial public offerings (IPOs), corporate governance, infrastructure projects, mutual funds, and small and medium enterprises (SMEs). The company primarily makes money by charging fees to its clients (issuers) for these rating and grading services.

Revenue Mix

Care Ratings operates primarily in the credit rating segment. Its revenue is predominantly derived from fees charged for assigning and monitoring credit ratings across a wide spectrum of instruments and entities. This includes corporate bond ratings, bank loan ratings, structured finance ratings, ratings for public finance, project finance, financial sector entities, and various grading assignments (e.g., IPO grading, governance ratings, real estate project ratings). While it may offer research and advisory services, the overwhelming majority of its revenue comes from its core rating business. Specific revenue breakdowns by instrument or client type are typically detailed in their annual reports.

Industry

The Indian credit rating industry is a highly regulated oligopoly, dominated by a few key players. Care Ratings is one of the top three or four significant credit rating agencies in India, alongside CRISIL (an S&P Global company), ICRA (a Moody's Investors Service company), and India Ratings & Research (a Fitch Group company). Care Ratings has established itself as a credible player with a significant market share, particularly in rating bank loans and various debt instruments, making it a prominent competitor to the larger, globally-affiliated agencies.

MOAT

Regulatory Barriers: The credit rating industry is highly regulated by SEBI, requiring stringent compliance and significant capital. This acts as a high entry barrier for new players.

Reputation and Credibility: Trust, independence, and an unblemished track record are paramount in the ratings business. Care Ratings, having operated for decades, has built a significant reputation and credibility among investors, issuers, and regulators.

Data and Analytical Expertise: Accumulated historical data, proprietary methodologies, and deep analytical expertise contribute to its competitive edge, making it difficult for new entrants to replicate.

Moderate Switching Costs: While not extremely high, issuers often prefer continuity with an established rating agency due to familiarity with processes, methodologies, and the agency's acceptance by lenders/investors.

Growth Drivers

Indian Economic Growth: A growing economy generally leads to increased corporate borrowing, capital expenditure, and new debt issuances, driving demand for credit ratings.

Deepening of Bond Market: Efforts by regulators to deepen India's corporate bond market will result in more companies raising capital through bonds, increasing the need for bond ratings.

Regulatory Mandates: Evolving SEBI and RBI regulations, such as mandatory credit ratings for bank loan exposures and certain market instruments, continuously expand the addressable market.

Infrastructure Spending: Government thrust on infrastructure development will necessitate project financing and related credit assessments.

Financialization of Economy: Increased formalization and reliance on structured finance will lead to a higher demand for various rating and grading services.

Risks

Reputational Risk: Any failure in accurately assessing creditworthiness, or perceived conflicts of interest, can severely damage credibility and lead to loss of business and regulatory scrutiny.

Intense Competition: The industry faces fierce competition from larger, globally-backed players (CRISIL, ICRA, India Ratings) who often have deeper pockets and wider international recognition.

Regulatory Changes: Adverse changes in SEBI regulations, fee caps, or increased compliance burdens could impact profitability and business models.

Economic Downturn: A slowdown in economic activity can reduce corporate borrowing and new debt issuances, negatively impacting revenue generation.

Cyclicality: The rating business is somewhat cyclical, tied to credit cycles and capital market activity.

Talent Retention: Attracting and retaining experienced credit analysts is crucial, and a competitive labor market poses a challenge.

Management & Ownership

Care Ratings Ltd. was initially promoted by leading financial institutions like IDBI Bank. Over time, it has evolved into a professionally managed, publicly listed company. While it does not have a single dominant promoter group in the traditional sense, it has a diversified ownership structure with institutional investors, corporate bodies, and public shareholders. The company typically operates with an independent board and experienced professionals, aiming for governance standards aligned with its role as a financial market utility.

Outlook

Care Ratings operates in a stable, regulated oligopolistic industry, benefiting from India's economic growth and deepening financial markets. The increasing formalization of the economy, regulatory push for ratings, and growth in debt capital markets provide a favorable backdrop for consistent revenue generation. However, it faces intense competition from larger, globally-affiliated peers who often have greater resources and market penetration. The inherent reputational risks of the credit rating business necessitate strong governance and analytical rigor. Its ability to maintain its independence, enhance analytical capabilities, and navigate competitive pressures while adhering to regulatory standards will be key determinants of its continued success.

Care Ratings Share Price

Live · BSE / NSE · Inception: 1993
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Consolidated · annual

Care Ratings Quarterly Results

#(Fig in Cr.) Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 90 79 117 96 110 94 136 112 131 112
Other Income 10 12 12 12 15 14 13 13 16 15
Total Income 100 91 129 108 125 108 149 125 146 126
Total Expenditure 61 57 62 66 62 66 68 72 70 77
Operating Profit 39 34 68 42 63 41 81 53 76 49
Interest 0 0 0 1 1 1 1 1 1 1
Depreciation 3 3 3 3 3 3 3 4 4 4
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 36 30 64 39 59 37 77 49 72 45
Provision for Tax 12 9 17 10 16 11 20 12 19 12
Profit After Tax 25 21 47 28 43 26 57 37 53 33
Adjustments -0 -1 -1 -1 -1 -1 -1 -1 -1 -1
Profit After Adjustments 24 21 46 28 43 26 57 36 53 32
Adjusted Earnings Per Share 8.1 6.9 15.4 9.3 14.2 8.6 18.9 12 17.6 10.7

Care Ratings Profit & Loss

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Net Sales 279 287 333 319 244 248 248 279 332 402 473 491
Other Income 9 34 25 30 31 31 27 38 47 51 55 57
Total Income 288 321 358 349 275 280 275 317 378 453 528 546
Total Expenditure 105 105 122 144 162 153 168 180 220 247 276 287
Operating Profit 183 216 236 205 113 127 107 137 159 206 252 259
Interest 0 0 0 0 1 1 0 1 2 2 2 4
Depreciation 4 3 3 3 8 8 8 11 10 12 14 15
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 178 212 233 202 104 119 99 126 147 192 235 243
Provision for Tax 59 65 71 64 21 28 22 40 44 52 62 63
Profit After Tax 120 148 162 138 83 91 77 85 103 140 174 180
Adjustments 0 0 0 -1 -1 -1 -2 -2 -2 -3 -3 -4
Profit After Adjustments 120 148 162 137 82 90 75 84 101 137 171 178
Adjusted Earnings Per Share 40.7 50.1 55.1 46.7 28 30.4 25.3 28.1 33.7 45.9 57 59.2

Care Ratings Balance Sheet

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Shareholder's Funds 409 520 597 550 533 589 647 672 717 806 932
Minority's Interest 0 0 2 2 3 4 5 7 7 9 11
Borrowings 0 0 0 0 0 0 0 0 0 0 0
Other Non-Current Liabilities 371 15 9 13 22 25 21 33 38 44 44
Total Current Liabilities 86 475 551 611 541 557 584 58 79 98 118
Total Liabilities 866 1010 1159 1177 1099 1175 1257 770 842 958 1105
Fixed Assets 64 61 60 83 93 85 96 107 109 119 122
Other Non-Current Assets 593 83 257 252 229 40 65 61 58 146 305
Total Current Assets 209 866 842 842 777 1050 1096 602 675 692 677
Total Assets 866 1010 1159 1177 1099 1175 1257 770 842 958 1105

Care Ratings Cash Flow

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Opening Cash & Cash Equivalents 13 12 13 24 20 7 12 18 49 38 49
Cash Flow from Operating Activities 106 119 134 109 67 86 68 82 91 123 148
Cash Flow from Investing Activities -41 -22 -25 83 27 -38 -27 13 -39 -58 -94
Cash Flow from Financing Activities -66 -96 -99 -195 -107 -43 -35 -63 -63 -54 -59
Net Cash Inflow / Outflow -1 1 11 -4 -13 5 6 32 -11 11 -6
Closing Cash & Cash Equivalent 12 13 24 20 7 12 18 49 38 49 43

Care Ratings Ratios

# Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Earnings Per Share (Rs) 40.68 50.13 55.13 46.66 27.96 30.38 25.33 28.12 33.67 45.85 56.97
CEPS(Rs) 42.1 51.27 56.17 47.99 30.97 33.52 28.51 32.32 37.87 50.69 62.59
DPS(Rs) 28 28 55 30 19.5 17 17 25 18 18 22
Book NAV/Share(Rs) 138.53 176.5 199.65 179.42 173.02 191.49 215.75 224.16 238.52 267.56 308.68
Core EBITDA Margin(%) 62.24 63.39 63.35 54.76 33.38 38.55 32.15 35.61 33.81 38.61 41.73
EBIT Margin(%) 63.86 73.93 70.06 63.24 43.1 48 40.02 45.43 44.72 48.31 50.28
Pre Tax Margin(%) 63.86 73.93 70.06 63.24 42.72 47.76 39.83 45.07 44.21 47.79 49.75
PAT Margin (%) 42.81 51.36 48.8 43.29 34.26 36.61 31.03 30.63 30.92 34.8 36.72
Cash Profit Margin (%) 44.31 52.54 49.74 44.33 37.45 39.75 34.14 34.4 34.08 37.71 39.75
ROA(%) 14.82 15.74 14.97 11.82 7.34 8 6.32 8.43 12.73 15.56 16.84
ROE(%) 31.49 31.85 29.3 24.73 16.08 16.94 12.76 13.09 14.89 18.51 20.1
ROCE(%) 46.48 45.76 41.74 35.18 19.39 21.26 16.03 19.21 21.35 25.52 27.36
Receivable days 25.71 31.06 35.4 49.49 66.03 45.73 28 24.22 23.59 24.75 25.89
Inventory Days 0 0 0 0 0 0 0 0 0 0 0
Payable days 0 0 0 0 0 0 0 0 0 0 0
PER(x) 22.92 33.06 21.96 21.18 11.79 13.53 20.21 22.86 33.18 24.01 25.27
Price/Book(x) 6.73 9.39 6.06 5.51 1.9 2.15 2.37 2.87 4.68 4.11 4.66
Dividend Yield(%) 3 1.69 4.54 3.04 5.92 4.13 3.32 3.89 1.61 1.64 1.53
EV/Net Sales(x) 9.77 16.93 10.63 9.03 3.51 3.71 5.8 6.64 9.88 7.95 8.87
EV/Core EBITDA(x) 14.94 22.54 14.98 14.05 7.59 7.25 13.45 13.5 20.63 15.52 16.64
Net Sales Growth(%) 7.22 2.89 15.74 -4.12 -23.62 1.97 -0.33 12.66 18.89 21.3 17.59
EBIT Growth(%) -9.98 19.11 9.69 -13.45 -47.94 13.56 -16.91 27.91 17.04 31.03 22.36
PAT Growth(%) -13.22 23.42 9.97 -14.95 -39.54 8.97 -15.54 11.23 20.02 36.5 24.07
EPS Growth(%) -14.41 23.24 9.97 -15.36 -40.08 8.67 -16.62 11.01 19.74 36.16 24.25
Debt/Equity(x) 0 0 0 0 0 0 0 0 0 0 0
Current Ratio(x) 2.43 1.82 1.53 1.38 1.44 1.88 1.88 10.41 8.57 7.08 5.76
Quick Ratio(x) 2.43 1.82 1.53 1.38 1.44 1.88 1.88 10.41 8.57 7.08 5.76
Interest Cover(x) 0 0 0 0 113.23 193.14 213.66 126.55 86.65 92.2 95.67
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0 0 0 0

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +18% +19% +14% +5%
Operating Profit CAGR +22% +23% +15% +3%
PAT CAGR +24% +27% +14% +4%
Share Price CAGR +3% +19% +18% +1%
ROE Average +20% +18% +16% +21%
ROCE Average +27% +25% +22% +29%

Care Ratings Shareholding Pattern

Latest · Sep 2026
100% held
Promoters 0 %
FII 23.6 %
DII (MF + Insurance) 32.22 %
Public (retail) 44.18 %
# Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Promoter 0000000000
FII 23.3724.824.7523.7424.6223.612323.2523.4123.6
DII 26.1525.2827.5129.3829.7631.631.331.3931.5832.22
Public 50.4849.9347.7446.8845.6244.7945.745.3745.0144.18
Others 0000000000
Total 100100100100100100100100100100

Care Ratings Peer Comparison

Care Ratings Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Care Ratings Pros & Cons

Pros

  • Company is almost debt free.

Cons

  • Promoter holding is low: 0%.
  • Stock is trading at 5.1 times its book value.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp